Aflac Opens the Bermuda Valve — and Passes the Keys

A $1 billion capital release out of Japanese cancer reserves, a portfolio-repositioning lever that is visibly running out of road, and a January handoff the tape hasn't repriced.

AFL · Earnings Call · 2026-11-05

The beat was plumbing; the plumbing was the point

Aflac's Q3 headline is a reserve convention, not an underwriting event. Adjusted EPS of $2.46 was down 1.2% year over year ex-FX, but inside that number sat a $0.71 gift from the annual actuarial assumption unlock — $447 million of pretax remeasurement gains on reserves including deferred profit liability, plus $55 million of experience remeasurement that was $2 million below plan. There was also $40 million, or $0.06 a share, of cybersecurity expense, and variable investment income $22 million light of long-term return expectations. Strip the unlock out and the quarter is unremarkable. CFO Max Broden was refreshingly plain about the mechanism: the unlock lowers future net premium ratios by 70 basis points in Japan, 60 in the U.S., and 320 at Aflac Re Bermuda — an ongoing, if small, tailwind to reported benefit ratio in Japan and its U.S. equivalent. What actually changed at this company is one line in the prepared remarks: Aflac Japan ceded roughly ¥500 billion of FSA-basis cancer reserves to Aflac Re Bermuda during the quarter, and management estimates that releases about $1 billion of capital over time available for redeployment. That is the thing to trade, not the $0.71.

So, post this transaction, we have ceded roughly 15% of our total FSA reserves from Aflac Japan to Aflac Bermuda... and we have an internal risk limit that we have set at 30%, that means that we have very meaningful runway to continue to execute further reinsurance transactions
Max Kristian Broden, Chief Financial Officer · 2026-11-05

The ladder matters because it shows the ambition ratcheting, and it shows the company delivering on what it pre-announced. In February, Broden described a midterm target of 10%: “to date, we've ceded roughly 6% of our Aflac Japan balance sheet to Bermuda. We have a midterm target to get to 10%.” — Max Broden, Senior Executive Vice President and CFO · 2026-02-05 By the August call the target had been reframed onto a different basis entirely: “this move from having a ceding limit from 10% of U.S. GAAP assets to 30% of FSA reserves, this is an internally imposed limit that we have developed ourselves.” — Max Broden, Senior Executive Vice President and CFO · 2026-08-07 Three months later the company is at 15% on an FSA basis, with roughly half the runway still untouched. The capital is real: an estimated regulatory ESR of 225%, 238% including the USP, combined RBC slightly above 575%, and adjusted leverage of 22.6% inside a 20%–25% corridor. And it is being spent fast. Aflac repurchased $804 million of stock and paid $305 million in dividends in the quarter — $1.1 billion total, $3.7 billion for the first nine months. Against a June-quarter free cash flow of just $112 million, that is a repurchase line running an order of magnitude above organic cash generation. Which is precisely the point of the Bermuda valve: it manufactures deployable capital rather than waiting for it.

Japan: the vault and the treadmill

Japan sales fell 4% to ¥18.8 billion, against the hardest comparison of the cycle — the Miraito cancer launch quarter of a year ago — but were up 3% through nine months and management still expects 2026 to exceed 2025. A cyber incident dented the quarter: direct mail and outbound calling were suspended, then resumed in September, and head of sales Koichiro Yoshizumi said October sales are back in line with expectations. Tsumitasu, the yen savings product, is now roughly 20% of sales, and Dan Amos was candid that it was not an obvious bet: “we were very cautious in getting into this business, and it has hit all the expectations that I have wanted so far” — Operator, Operator · 2026-11-05 Crucially, Broden argues total first-sector savings in force is still shrinking — legacy WAYS runoff exceeds new Tsumitasu — so the capital-intensity worry that hangs over this product line is, for now, a theoretical one. Guidance moved up: the Japan benefit ratio should come in slightly below the 60%–63% range, the expense ratio at the low end of 20%–23%, and the pretax profit margin range for Aflac Japan was raised to 35%–38%.

The fading lever

Here is the most interesting tension on the call. Aflac has spent three quarters celebrating its portfolio repositioning — selling low-yielding JGBs and legacy dollar paper into the highest interest rates in a generation. This quarter it moved another $2.3 billion, taking the year-to-date total to $7 billion and adding more than $80 million of annualized net investment income. But CIO Brad Dyslin effectively called the top on the lever's contribution:

We are gonna continue to look at this. The more we do, the harder it is to find additional opportunities... it is going to be difficult to have the same level of impact that we have had so far.
Bradley E. Dyslin, Chief Investment Officer · 2026-11-05

That is the language of a maturing trade, and the company's own keyword history corroborates it: switch trade and FSA basis are fresh top-five themes this quarter, whereas repositioning language itself is now flagged as a decelerating theme rather than an accelerating one. Meanwhile two things management used to lead with have quietly fallen out of the narrative: tax-credit investment volumes and the private credit build were top-ranked themes in earlier quarters and are barely audible today, reduced to a single sentence about boosting loan reserves against commercial real estate valuations. What management stops talking about is a signal. There is also a sharp contrast with insurance peers reporting in the same window: several P&C names are wrestling with casualty reserve strengthening and adverse loss trend, while Aflac is booking favorable unlocks. The one place the industry's new bogeyman intrudes — behavioral health claims pressure on group disability — Aflac swats away. Virgil Miller: "it is materially small for us at the time right now. Overall, I am very pleased with the growth that we are seeing in our life and disability overall business."

Passing the keys — at 12x earnings

The genuinely new material is the succession. Effective January 1, 2027, Shinsuke Morimoto becomes president of Aflac Japan and representative director, and Fred Samard becomes president of Aflac U.S., with Masatoshi Koide moving to chairman of Aflac Japan and Charles Lake taking the chairmanship of Aflac International. Amos framed it as deliberate board-led planning. The tell that it is real, not ceremonial: Miller visibly handed live questions to his successor mid-call, and the new names are already surfacing as distinct emerging themes. Finally, the valuation backdrop. The shares are up 6.5% over the past 90 trading days and carry a price-to-earnings multiple near 12.1x, down roughly 48% year over year because the denominator jumped while the numerator barely moved. That is the arithmetic behind Broden's claim of "good relative IRR on these capital deployments" — buying back stock at ~12x earnings with capital freed from Japanese reserves at an accounting cost rather than a cash one. The tension worth watching: whether the Bermuda runway and the switch-trade carry can keep funding a $3.7 billion annual capital return, or whether a fading repositioning lever and an $112 million free-cash-flow quarter force the growth conversation forward.